Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites
- 894 Downloads
Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes. Recently, we developed a combination chemotherapy that used intraperitoneal (IP) paclitaxel (PTX) and produced excellent antitumor effects against peritoneal lesions. However, no information is available about the benefit of gastrectomy in cases with malignant ascites.
A total of 64 patients with severe peritoneal metastasis and ascites received IP PTX at 20 mg/m2 via implanted subcutaneous peritoneal access ports as well as intravenous (IV) PTX at 50 mg/m2 on days 1 and 8. S-1 was administered at 80 mg/m2 day for 14 consecutive days, followed by 7 days of rest. In all patients, investigative laparoscopy was performed around the combination chemotherapy, and gastrectomy was performed on patients who showed apparent shrinkage of their peritoneal nodules as well as negative peritoneal cytology at the second laparoscopy.
Gastrectomy was performed in 34 patients. The median course of chemotherapy before surgery was 5 courses (range 2–16). R0 operation was achieved in 22 patients (65 %), and grade 2 and 3 histological responses were obtained in 7 (21 %) and 1 (3 %) patient(s), respectively. The median survival time and 1-year overall survival of the gastrectomized patients were 26.4 months and 82 %, and those of the 30 patients who did not receive gastrectomy were 12.1 months and 26 %, respectively. Morbidity was minimal, and there was no mortality.
Salvage gastrectomy after chemotherapy of S-1 with IV and IP PTX is promising, even for patients with highly advanced gastric cancer and severe peritoneal metastasis and malignant ascites.
KeywordsGastric Cancer Median Survival Time Advanced Gastric Cancer Peritoneal Metastasis Peritoneal Dissemination
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and a Grant from the Ministry of Health and Welfare of Japan.
- 3.Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRefGoogle Scholar
- 6.Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316–22.PubMedCrossRefGoogle Scholar
- 8.Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). In 2009 ASCO Annual Meeting. 2009; suppl; abstr 4545.Google Scholar
- 11.Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.PubMedCentralPubMedCrossRefGoogle Scholar
- 13.Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.PubMedCrossRefGoogle Scholar
- 26.Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102:200–5.PubMedCrossRefGoogle Scholar